Savant Capital LLC Sells 3,452 Shares of IDEXX Laboratories, Inc. $IDXX

Savant Capital LLC decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 79.1% during the 4th quarter, Holdings Channel.com reports. The fund owned 914 shares of the company’s stock after selling 3,452 shares during the quarter. Savant Capital LLC’s holdings in IDEXX Laboratories were worth $618,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Intech Investment Management LLC boosted its holdings in IDEXX Laboratories by 966.0% in the fourth quarter. Intech Investment Management LLC now owns 35,094 shares of the company’s stock valued at $23,742,000 after acquiring an additional 31,802 shares during the last quarter. Foundations Investment Advisors LLC boosted its holdings in IDEXX Laboratories by 4.3% during the fourth quarter. Foundations Investment Advisors LLC now owns 897 shares of the company’s stock worth $607,000 after buying an additional 37 shares during the last quarter. Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust bought a new position in IDEXX Laboratories during the fourth quarter worth about $5,880,000. Huntington National Bank boosted its holdings in IDEXX Laboratories by 1.8% during the fourth quarter. Huntington National Bank now owns 3,829 shares of the company’s stock worth $2,590,000 after buying an additional 69 shares during the last quarter. Finally, IPG Investment Advisors LLC bought a new position in IDEXX Laboratories during the fourth quarter worth about $1,499,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 1.8%

NASDAQ:IDXX opened at $560.73 on Thursday. IDEXX Laboratories, Inc. has a fifty-two week low of $506.91 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The stock has a market capitalization of $44.23 billion, a PE ratio of 41.29, a price-to-earnings-growth ratio of 3.20 and a beta of 1.55. The business’s 50-day simple moving average is $563.43 and its 200-day simple moving average is $633.51.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the previous year, the business posted $2.91 EPS. IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Barclays reduced their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Piper Sandler reduced their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Finally, Stifel Nicolaus reduced their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.